Susvimo Demonstrates Sustained Efficacy Over Two Years in Patients with Diabetic Macular Edema and Diabetic Retinopathy
Image credit: koolsabuy | stock.adobe.com Two-year data from the Phase III Pagoda and Pavilion studies demonstrate that Genentech’s Susvimo (ranibizumab) injection 100 mg/mL produced sustained efficacy in patients with diabetic macular edema (DME) and diabetic retinopathy (DR), respectively. The FDA accepted a supplemental Biologics License Application (sBLA) for Susvimo based on one-year results showing non-inferior […]
Continue Reading